These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 18192258)

  • 1. Elevated serum creatinine levels associated with fenofibrate therapy.
    McQuade CR; Griego J; Anderson J; Pai AB
    Am J Health Syst Pharm; 2008 Jan; 65(2):138-41. PubMed ID: 18192258
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fenofibrate increases serum creatinine in a patient with familial nephropathy associated to hyperuricemia.
    Salgueiro G; Beltrán LM; Torres RJ; Puig JG
    Nucleosides Nucleotides Nucleic Acids; 2014; 33(4-6):181-4. PubMed ID: 24940667
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fenofibrate and the kidney: an overview.
    Kostapanos MS; Florentin M; Elisaf MS
    Eur J Clin Invest; 2013 May; 43(5):522-31. PubMed ID: 23480615
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improvement in Kidney Function after Discontinuation of Fenofibrate in Outpatient Nephrology Consultation for Chronic Kidney Disease.
    Hernandez-Arroyo CF; Kanduri SR; Justiniano R; Martinez-Pitre PJ; Velez JCQ
    Kidney Blood Press Res; 2022; 47(9):586-591. PubMed ID: 35609528
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reversibility of fenofibrate therapy-induced renal function impairment in ACCORD type 2 diabetic participants.
    Mychaleckyj JC; Craven T; Nayak U; Buse J; Crouse JR; Elam M; Kirchner K; Lorber D; Marcovina S; Sivitz W; Sperl-Hillen J; Bonds DE; Ginsberg HN
    Diabetes Care; 2012 May; 35(5):1008-14. PubMed ID: 22432114
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of fenofibrate therapy on renal function in primary gout patients.
    Li X; Sun W; Lu J; He Y; Chen Y; Ren W; Cui L; Liu Z; Wang C; Wang X; Ma L; Cheng X; Han L; Li H; Zhang H; Yuan X; Ji X; Ji A; Merriman TR; Li C
    Rheumatology (Oxford); 2021 Nov; 60(11):5020-5027. PubMed ID: 33704429
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fibrate-induced increase in blood urea and creatinine: is gemfibrozil the only innocuous agent?
    Broeders N; Knoop C; Antoine M; Tielemans C; Abramowicz D
    Nephrol Dial Transplant; 2000 Dec; 15(12):1993-9. PubMed ID: 11096145
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the incidence and risk factors for development of fenofibrate-associated nephrotoxicity.
    Attridge RL; Linn WD; Ryan L; Koeller J; Frei CR
    J Clin Lipidol; 2012; 6(1):19-26. PubMed ID: 22264570
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fenofibrate-associated nephrotoxicity: a review of current evidence.
    Attridge RL; Frei CR; Ryan L; Koeller J; Linn WD
    Am J Health Syst Pharm; 2013 Jul; 70(14):1219-25. PubMed ID: 23820458
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fenofibrate increases creatininemia by increasing metabolic production of creatinine.
    Hottelart C; El Esper N; Rose F; Achard JM; Fournier A
    Nephron; 2002; 92(3):536-41. PubMed ID: 12372935
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Benefits and safety of long-term fenofibrate therapy in people with type 2 diabetes and renal impairment: the FIELD Study.
    Ting RD; Keech AC; Drury PL; Donoghoe MW; Hedley J; Jenkins AJ; Davis TM; Lehto S; Celermajer D; Simes RJ; Rajamani K; Stanton K;
    Diabetes Care; 2012 Feb; 35(2):218-25. PubMed ID: 22210576
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fenofibrate, homocysteine and renal function.
    Foucher C; Brugère L; Ansquer JC
    Curr Vasc Pharmacol; 2010 Sep; 8(5):589-603. PubMed ID: 20507276
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Probable fenofibrate-induced acute generalized exanthematous pustulosis.
    Power AE; Graudins LV; McLean CA; Hopper I
    Am J Health Syst Pharm; 2015 Dec; 72(23):2061-3. PubMed ID: 26581932
    [TBL] [Abstract][Full Text] [Related]  

  • 14. False estimates of elevated creatinine.
    Samra M; Abcar AC
    Perm J; 2012; 16(2):51-2. PubMed ID: 22745616
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fenofibrate-Induced elevation in serum creatinine.
    Ritter JL; Nabulsi S
    Pharmacotherapy; 2001 Sep; 21(9):1145-9. PubMed ID: 11560205
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The relationship between serum creatinine and estimated glomerular filtration rate: implications for clinical practice.
    Nelson AW; Mackinnon B; Traynor J; Geddes CC
    Scott Med J; 2006 Nov; 51(4):5-9. PubMed ID: 17137139
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of fenofibrate and gemfibrozil on plasma homocysteine.
    Westphal S; Dierkes J; Luley C
    Lancet; 2001 Jul; 358(9275):39-40. PubMed ID: 11454380
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiac Angiography in Renally Impaired Patients (CARE) study: a randomized double-blind trial of contrast-induced nephropathy in patients with chronic kidney disease.
    Solomon RJ; Natarajan MK; Doucet S; Sharma SK; Staniloae CS; Katholi RE; Gelormini JL; Labinaz M; Moreyra AE;
    Circulation; 2007 Jun; 115(25):3189-96. PubMed ID: 17562951
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fibrate-induced increase in blood urea and creatinine.
    Lipscombe J; Bargman JM
    Nephrol Dial Transplant; 2001 Jul; 16(7):1515. PubMed ID: 11427661
    [No Abstract]   [Full Text] [Related]  

  • 20. Fenofibrate-induced hepatotoxicity: A case with a special feature that is different from those in the LiverTox database.
    Ma S; Liu S; Wang Q; Chen L; Yang P; Sun H
    J Clin Pharm Ther; 2020 Feb; 45(1):204-207. PubMed ID: 31518450
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.